Cargando…
Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors
Background. The purpose of the study was to evaluate Sorafenib (BAY 43-9006) derived receptor tyrosine kinase inhibition on tumor progression in murine islet cell tumors. Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors. Rip1Tag2 m...
Autores principales: | Fendrich, Volker, Maschuw, Katja, Rehm, Johannes, Buchholz, Malte, Holler, Julia P., Slater, Emily P., Bartsch, Detlef K., Waldmann, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific World Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543792/ https://www.ncbi.nlm.nih.gov/pubmed/23346016 http://dx.doi.org/10.1100/2012/529151 |
Ejemplares similares
-
Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine Tumors
por: Fendrich, Volker, et al.
Publicado: (2012) -
A Pancreatic Polypeptide-Producing Pancreatic Tumor Causing WDHA Syndrome
por: Amrilleva, Vera, et al.
Publicado: (2008) -
Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer()()
por: Knoop, Richard F., et al.
Publicado: (2014) -
Palladin Mutation Causes Familial Pancreatic Cancer: Absence in European Families
por: Slater, Emily, et al.
Publicado: (2007) -
Fast-growing pancreatic neuroendocrine carcinoma in a patient with multiple endocrine neoplasia type 1: a case report
por: Waldmann, Jens, et al.
Publicado: (2008)